NASDAQ:CTSO - Cytosorbents Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $12.35 -0.20 (-1.59 %) (As of 07/15/2018 02:59 PM ET)Previous Close$12.35Today's Range$12.10 - $12.6552-Week Range$4.25 - $12.70Volume192,102 shsAverage Volume442,188 shsMarket Capitalization$370.90 millionP/E Ratio-38.59Dividend YieldN/ABeta-0.02 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey. Receive CTSO News and Ratings via Email Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:CTSO CUSIPN/A Webwww.cytosorbents.com Phone732-329-8885 Debt Debt-to-Equity Ratio0.68 Current Ratio6.16 Quick Ratio5.99 Price-To-Earnings Trailing P/E Ratio-38.59 Forward P/E Ratio-25.73 P/E GrowthN/A Sales & Book Value Annual Sales$15.15 million Price / Sales24.48 Cash FlowN/A Price / CashN/A Book Value$0.36 per share Price / Book34.31 Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-8,460,000.00 Net Margins-56.06% Return on Equity-88.39% Return on Assets-38.47% Miscellaneous Employees84 Outstanding Shares30,030,000Market Cap$370.90 Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." How were Cytosorbents' earnings last quarter? Cytosorbents Corp (NASDAQ:CTSO) released its earnings results on Tuesday, May, 8th. The medical research company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03. The medical research company had revenue of $4.93 million for the quarter, compared to the consensus estimate of $4.56 million. Cytosorbents had a negative return on equity of 88.39% and a negative net margin of 56.06%. View Cytosorbents' Earnings History. When is Cytosorbents' next earnings date? Cytosorbents is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Cytosorbents. What price target have analysts set for CTSO? 5 analysts have issued 1 year target prices for Cytosorbents' stock. Their predictions range from $9.00 to $14.00. On average, they expect Cytosorbents' share price to reach $11.25 in the next twelve months. This suggests that the stock has a possible downside of 8.9%. View Analyst Ratings for Cytosorbents. What is the consensus analysts' recommendation for Cytosorbents? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Cytosorbents? Cytosorbents saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 2,667,813 shares, an increase of 68.8% from the June 15th total of 1,580,330 shares. Based on an average trading volume of 658,144 shares, the short-interest ratio is currently 4.1 days. Currently, 10.3% of the shares of the stock are sold short. View Cytosorbents' Current Options Chain. Who are some of Cytosorbents' key competitors? Some companies that are related to Cytosorbents include Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), OraSure Technologies (OSUR), Intersect ENT (XENT), AtriCure (ATRC), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cerus (CERS), SurModics (SRDX) and AngioDynamics (ANGO). Who are Cytosorbents' key executives? Cytosorbents' management team includes the folowing people: Dr. Phillip P. Chan, CEO, Pres & Director (Age 48)Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79) Has Cytosorbents been receiving favorable news coverage? Media headlines about CTSO stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytosorbents earned a media sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. How do I buy shares of Cytosorbents? Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $12.35. How big of a company is Cytosorbents? Cytosorbents has a market capitalization of $370.90 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected] MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)Community Ranking: 3.7 out of 5 ( )Outperform Votes: 288 (Vote Outperform)Underperform Votes: 97 (Vote Underperform)Total Votes: 385MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?